Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio per indagare l'efficacia e la sicurezza di anifrolumab negli adulti con lupus eritematoso cutaneo cronico e/o subacuto (LAVENDER)

10 novembre 2026 aggiornato da: AstraZeneca

Uno studio di fase III multicentrico, randomizzato, in doppio cieco, controllato con placebo per valutare l'efficacia e la sicurezza di anifrolumab negli adulti con lupus eritematoso cutaneo cronico e/o subacuto refrattari e/o intolleranti alla terapia antimalarica

This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with chronic and/or subacute cutaneous lupus erythematosus (CLE).

Panoramica dello studio

Stato

Attivo, non reclutante

Condizioni

Intervento / Trattamento

Descrizione dettagliata

This is a multicenter, randomized, double-blind, placebo-controlled, Phase III study to evaluate the efficacy and safety of anifrolumab in adults with chronic and/or subacute CLE who are refractory and/or intolerant to antimalarial therapy. The study has a randomized, 24-week double-blind, placebo-controlled study period (Week 0 to Week 23), to evaluate the efficacy and safety of anifrolumab. The double-blind study period will be followed by an open-label, uncontrolled treatment period in which all participants will receive treatment with anifrolumab from Week 24 to Week 51. After the open-label treatment period, participants will enter a 12-week Safety Follow-up Period.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

339

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Ciudad de Buenos Aires, Argentina, 1221
        • Research Site
      • Córdoba, Argentina, 5000
        • Research Site
      • Córdoba, Argentina, X5004BAL
        • Research Site
      • Quilmes, Argentina, 1878
        • Research Site
      • San Miguel, Argentina, 1663
        • Research Site
      • Kogarah, Australia, 3168
        • Research Site
      • Melbourne, Australia, 3004
        • Research Site
      • Mitcham, Australia, 3132
        • Research Site
      • Westmead, Australia, 2145
        • Research Site
      • Woolloongabba, Australia, 04102
        • Research Site
      • Graz, Austria, 8036
        • Research Site
      • Innsbruck, Austria, 6020
        • Research Site
      • Linz, Austria, 4020
        • Research Site
      • Vienna, Austria, 1130
        • Research Site
      • Belo Horizonte, Brasile, 30150-221
        • Research Site
      • Porto Alegre, Brasile, 90035903
        • Research Site
      • Rio de Janeiro, Brasile, 22470-220
        • Research Site
      • Salvador, Brasile, 40150-150
        • Research Site
      • São Paulo, Brasile, 05403-000
        • Research Site
      • Sofia, Bulgaria, 1784
        • Research Site
      • Sofia, Bulgaria, 1463
        • Research Site
      • Sofia, Bulgaria, 1528
        • Research Site
    • British Columbia
      • Vancouver, British Columbia, Canada, V5Z 1M9
        • Research Site
    • Ontario
      • Hamilton, Ontario, Canada, L8N 3Z5
        • Research Site
      • Toronto, Ontario, Canada, M5T 2S8
        • Research Site
      • Osorno, Chile, 200025
        • Research Site
      • Santiago, Chile, 7500571
        • Research Site
      • Santiago, Chile, 130021
        • Research Site
      • Changchun, Cina, 130021
        • Research Site
      • Changsha, Cina, 410011
        • Research Site
      • Chengdu, Cina, 610021
        • Research Site
      • Chongqing, Cina, 400016
        • Research Site
      • Dongguan, Cina, 523059
        • Research Site
      • Guangzhou, Cina, 510120
        • Research Site
      • Heilongjiang, Cina, 150086
        • Research Site
      • Jinan, Cina, 250022
        • Research Site
      • Shanghai, Cina, 200025
        • Research Site
      • Shanghai, Cina, 200443
        • Research Site
      • Shenzhen, Cina, 518053
        • Research Site
      • Shenzhen, Cina, 518020
        • Research Site
      • Shenzhen, Cina, 518052
        • Research Site
      • Zhuzhou, Cina, 412007
        • Research Site
      • Ürümqi, Cina, CN-830004
        • Research Site
      • Barranquilla, Colombia, 080020
        • Research Site
      • Bogotá, Colombia, 110221
        • Research Site
      • Seoul, Corea del Sud, 03080
        • Research Site
      • Seoul, Corea del Sud, 06591
        • Research Site
      • Seoul, Corea del Sud, 06973
        • Research Site
      • Aarhus, Danimarca, 641-8510
        • Research Site
      • Copenhagen, Danimarca, 2100
        • Research Site
      • Iloilo City, Filippine, 5000
        • Research Site
      • Lipa, Filippine, 4217
        • Research Site
      • Manila, Filippine, 1000
        • Research Site
      • Bois-Guillaume, Francia, 76031
        • Research Site
      • Dijon, Francia, 21000
        • Research Site
      • Lyon, Francia, 69437
        • Research Site
      • Montivilliers, Francia, 76290
        • Research Site
      • Nantes, Francia, 44000
        • Research Site
      • Paris, Francia, 75010
        • Research Site
      • Paris, Francia, 75014
        • Research Site
      • Paris, Francia, 75013
        • Research Site
      • Paris, Francia, 75970
        • Research Site
      • Poitiers, Francia, 86000, FR
        • Research Site
      • Toulouse, Francia, 31059
        • Research Site
      • Berlin, Germania, 10117
        • Research Site
      • Bochum, Germania, 44791
        • Research Site
      • Dresden, Germania, 01307
        • Research Site
      • Erlangen, Germania, 91054
        • Research Site
      • Essen, Germania, 45147
        • Research Site
      • Freiburg im Breisgau, Germania, 79104
        • Research Site
      • Hanover, Germania, 30625
        • Research Site
      • Kiel, Germania, 24105
        • Research Site
      • Leipzig, Germania, 04103
        • Research Site
      • Mainz, Germania, 55131
        • Research Site
      • Marburg, Germania, 35043
        • Research Site
      • Regensburg, Germania, 93053
        • Research Site
      • Wuppertal, Germania, 42283
        • Research Site
      • Chūōku, Giappone, 104-8560
        • Research Site
      • Fukuoka, Giappone, 812-8582
        • Research Site
      • Kanazawa, Giappone, 920-8641
        • Research Site
      • Kita-gun, Giappone, 761-0793
        • Research Site
      • Nagoya, Giappone, 457-8510
        • Research Site
      • Nagoya, Giappone, 467-8602
        • Research Site
      • Wakayama, Giappone, 641-8510
        • Research Site
      • Yokohama, Giappone, 232-0024
        • Research Site
      • tabashi City, Giappone, 173-8606
        • Research Site
      • Athens, Grecia, 12462
        • Research Site
      • Athens, Grecia, 16121
        • Research Site
      • Brescia, Italia, 25123
        • Research Site
      • Cona, Italia, 44124
        • Research Site
      • Florence, Italia, 50121
        • Research Site
      • Milan, Italia, 20132
        • Research Site
      • Naples, Italia, 80138
        • Research Site
      • Reggio Emilia, Italia, 42123
        • Research Site
      • Roma, Italia, 00144
        • Research Site
      • Rome, Italia, 00168
        • Research Site
      • Guadalajara, Messico, 44340
        • Research Site
      • Guadalajara, Messico, 44610
        • Research Site
      • Mexico City, Messico, 07760
        • Research Site
      • Veracruz, Messico, 91910
        • Research Site
      • Papatoetoe, Nuova Zelanda, 2025
        • Research Site
      • Breda, Olanda, 4818 CK
        • Research Site
      • Rotterdam, Olanda, 3015 GD
        • Research Site
      • Katowice, Polonia, 40-851
        • Research Site
      • Kielce, Polonia, 25-316
        • Research Site
      • Ossy, Polonia, 40-027
        • Research Site
      • Rzeszów, Polonia, 35-055
        • Research Site
      • Warsaw, Polonia, 02-637
        • Research Site
      • Braga, Portogallo, 4710-243
        • Research Site
      • Lisbon, Portogallo, 1649-035
        • Research Site
      • Porto, Portogallo, 4099-001
        • Research Site
      • Cambridge, Regno Unito, CB2 0QQ
        • Research Site
      • Leeds, Regno Unito, LS2 9JT
        • Research Site
      • London, Regno Unito, NW1 2PG
        • Research Site
      • London, Regno Unito, SE5 9RS
        • Research Site
      • London, Regno Unito, SE1 7EH
        • Research Site
      • London, Regno Unito, NW3 2QG
        • Research Site
      • Newcastle upon Tyne, Regno Unito, NE1 4LP
        • Research Site
      • Bucharest, Romania, 020125
        • Research Site
      • Iași, Romania, 700291
        • Research Site
      • Belgrade, Serbia, 11000
        • Research Site
      • Kragujevac, Serbia, 34000
        • Research Site
      • Košice, Slovacchia, 04001
        • Research Site
      • Piešťany, Slovacchia, 92101
        • Research Site
      • Barcelona, Spagna, 8035
        • Research Site
      • Barcelona, Spagna, 08025
        • Research Site
      • Castellon, Spagna, 12004
        • Research Site
      • Granada, Spagna, 18012
        • Research Site
      • L'Hospitalet de Llobregat, Spagna, 08907
        • Research Site
      • Las Palmas de Gran Canaria, Spagna, 35010
        • Research Site
      • Madrid, Spagna, 28034
        • Research Site
      • Madrid, Spagna, 28041
        • Research Site
      • Madrid, Spagna, 28040
        • Research Site
      • Madrid, Spagna, 28006
        • Research Site
      • Majadahonda, Spagna, 28222
        • Research Site
      • Salamanca, Spagna, 37007
        • Research Site
      • Seville, Spagna, 41014
        • Research Site
      • Valencia, Spagna, 46014
        • Research Site
      • Valencia, Spagna, 46017
        • Research Site
      • Vigo, Spagna, 36200
        • Research Site
    • Arizona
      • Phoenix, Arizona, Stati Uniti, 85028
        • Research Site
    • California
      • Covina, California, Stati Uniti, 91722
        • Research Site
      • La Jolla, California, Stati Uniti, 92037
        • Research Site
      • Los Angeles, California, Stati Uniti, 90045
        • Research Site
      • Los Angeles, California, Stati Uniti, 90089
        • Research Site
      • Orange, California, Stati Uniti, 92868
        • Research Site
      • San Francisco, California, Stati Uniti, 94143
        • Research Site
    • Colorado
      • Aurora, Colorado, Stati Uniti, 80045
        • Research Site
    • Connecticut
      • New Haven, Connecticut, Stati Uniti, 06519
        • Research Site
    • District of Columbia
      • Washington D.C., District of Columbia, Stati Uniti, 20037
        • Research Site
    • Florida
      • Fort Lauderdale, Florida, Stati Uniti, 33309
        • Research Site
      • Miami, Florida, Stati Uniti, 33174
        • Research Site
      • Plantation, Florida, Stati Uniti, 33324
        • Research Site
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60637
        • Research Site
      • Chicago, Illinois, Stati Uniti, 60611
        • Research Site
    • Indiana
      • Indianapolis, Indiana, Stati Uniti, 46202
        • Research Site
    • Maryland
      • Baltimore, Maryland, Stati Uniti, 21287
        • Research Site
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02114
        • Research Site
      • Boston, Massachusetts, Stati Uniti, 02115-5817
        • Research Site
    • Michigan
      • Ann Arbor, Michigan, Stati Uniti, 48109
        • Research Site
      • Bloomfield Hills, Michigan, Stati Uniti, 48302
        • Research Site
    • Minnesota
      • Rochester, Minnesota, Stati Uniti, 55905
        • Research Site
    • Nebraska
      • Omaha, Nebraska, Stati Uniti, 68198-5885
        • Research Site
    • New York
      • New York, New York, Stati Uniti, 10028
        • Research Site
      • Rochester, New York, Stati Uniti, 14642
        • Research Site
    • North Carolina
      • Charlotte, North Carolina, Stati Uniti, 28207
        • Research Site
      • Statesville, North Carolina, Stati Uniti, 28625
        • Research Site
    • Ohio
      • Cleveland, Ohio, Stati Uniti, 44195
        • Research Site
    • Oregon
      • Portland, Oregon, Stati Uniti, 97239
        • Research Site
    • Rhode Island
      • Providence, Rhode Island, Stati Uniti, 02903
        • Research Site
    • South Carolina
      • Charleston, South Carolina, Stati Uniti, 29425
        • Research Site
    • Texas
      • Dallas, Texas, Stati Uniti, 75390-8843
        • Research Site
    • Virginia
      • Charlottesville, Virginia, Stati Uniti, 22903
        • Research Site
      • Roanoke, Virginia, Stati Uniti, 24016
        • Research Site
      • Cape Town, Sud Africa, 7500
        • Research Site
      • Johannesburg, Sud Africa, 2193
        • Research Site
      • Bangkok, Tailandia, 10330
        • Research Site
      • Bangkok, Tailandia, 10700
        • Research Site
      • Hat Yai, Tailandia, 90110
        • Research Site
      • Khlong Luang, Tailandia, 12120
        • Research Site
      • Khon Kaen, Tailandia, 40002
        • Research Site
      • Kaohsiung City, Taiwan, 83301
        • Research Site
      • Taichung, Taiwan, 404
        • Research Site
      • Taipei, Taiwan, 10449
        • Research Site
      • Cordaleo, Turchia (Türkiye), 35575
        • Research Site
      • Istanbul, Turchia (Türkiye), 34098
        • Research Site
      • Kayseri, Turchia (Türkiye), 38039
        • Research Site
      • Samsun, Turchia (Türkiye), 55270
        • Research Site

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 70 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Key inclusion criteria:

  • Participants must have a confirmed diagnosis of CLE. Diagnosis must be clinically and histologically confirmed with the following:

    • CLASI-A total score ≥ 10 points at Screening and confirmed at randomization.
    • Inadequate response or intolerant to antimalarial therapy.
  • Participants should have no medical history or signs or symptoms of active or prior tuberculosis infection (TB) and the same should reflect in chest radiograph or a chest CT scan result.

  • Contraceptive use by males and females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Key exclusion criteria:

  • History or evidence of suicidal ideation.
  • Severe or life-threatening Systemic lupus erythematosus (SLE).
  • Active SLE or Sjögren's Syndrome.
  • Any active skin conditions other than CLE that may interfere with the study.
  • History of, or current diagnosis of, catastrophic antiphospholipid syndrome (APS).
  • History of recurrent infection requiring hospitalization and IV antibiotics.
  • COVID-19 infection.
  • Any history of an anaphylactic reaction to human proteins, or monoclonal antibodies.
  • At screening, if participants do not meet the eligibility criteria assessed based on laboratory test results e.g tests for total bilirubin, serum creatinine etc.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Anifrolumab

Participants will receive anifrolumab as a SC injection from Week 0/Day 1 up to Week 51.

Anifrolumab will be provided as a solution for injection in accessorized pre-filled syringe (aPFS).

Comparatore placebo: Placebo

Participants will receive placebo as a SC injection from Week 0/Day 1 up to Week 23. From Week 24 the participants will receive anifrolumab up to and including Week 51.

Matching placebo solution for injection in aPFS.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Number of participants with a 70% reduction relative to baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) score
Lasso di tempo: At Week 24

The CLASI is a validated index used for assessing the cutaneous lesions of SLE. It consists of 2 separate scores: i) activity of the disease, and ii) measure of damage. The CLASI instrument will be used at each study visit to capture individual skin manifestation scores. CLASI-70 responder (Yes/No) is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder.

At Week 24

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change from baseline in total CLASI-A score
Lasso di tempo: At Week 24

The CLASI-A is a validated index used for assessing the cutaneous lesions of SLE.

At Week 24
Number of participants with CLASI-70 response
Lasso di tempo: At Week 12

The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-70 responder is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder.

At Week 12
Number of participants with ≥ 7-point reduction from baseline in CLASI-A total score
Lasso di tempo: At Week 12

The CLASI is a validated index used for assessing the cutaneous lesions of SLE. A 7-point reduction CLASI-A is established as clinically meaningful improvement in disease for CLE and as being impactful for patients.

At Week 12
Number of participants with CLASI-50 response
Lasso di tempo: At Week 12 and Week 24

The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-50 responder is defined as a responder (yes/no) is defined as a participant who achieves at least a 50% reduction relative to baseline in CLASI-A score. Otherwise, the participant is a non-responder.

At Week 12 and Week 24
Number of participants who are sustained CLASI-70 responders
Lasso di tempo: Up to Week 52

The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-70 responder is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. Amongst participants randomized to anifrolumab, the number of participants who maintained a CLASI-70 response from Week 24 up to Week 52 will be evaluated.

Up to Week 52
Serum trough (pre-dose) concentrations of anifrolumab
Lasso di tempo: Double-blind: Pre-dose on Day 1 (Week 0), Weeks 1, 4, 12, 24; Open-label: Weeks 40, and 52 or early discontinuation visit [EDV] and follow-up visit (13 Weeks after last dose)

The Ctrough of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated.

Double-blind: Pre-dose on Day 1 (Week 0), Weeks 1, 4, 12, 24; Open-label: Weeks 40, and 52 or early discontinuation visit [EDV] and follow-up visit (13 Weeks after last dose)
Number of participants with positive antidrug antibody
Lasso di tempo: Double-blind: Pre-dose on Day 1 (Week 0), Weeks 4, 12, and 24; Open-label: Pre-dose on Weeks 40, and 52 or EDV and follow-up visit (13 weeks after last dose)

The immunogenicity of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated.

Double-blind: Pre-dose on Day 1 (Week 0), Weeks 4, 12, and 24; Open-label: Pre-dose on Weeks 40, and 52 or EDV and follow-up visit (13 weeks after last dose)
Percent change from baseline in suppression of the Interferon 21-gene
Lasso di tempo: Double-blind: Day 1 (Week 0), Week 1, 4, 12, and 24; Open-label; Week 40 and 52 or EDV and follow-up visit (13 weeks after last dose)

The pharmacodynamics of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated.

Double-blind: Day 1 (Week 0), Week 1, 4, 12, and 24; Open-label; Week 40 and 52 or EDV and follow-up visit (13 weeks after last dose)
Change from baseline in Skindex-29+3 Symptom domain scores
Lasso di tempo: At Week 24

The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. The instrument consists of 33 items, which are used to calculate 4 domains: Symptoms (7 items), Emotions (10 items), Functioning (12 items), and Lupus-specific (3 items). The remaining item asks the participants to rate how often they worry about side effects from treatment; however, this item is not used to calculate the domain scores. The response options are on a 5-point verbal rating scale, ranging from 1 (Never) to 5 (All the time). The instrument has a recall period of the previous 4 weeks. Each domain score ranges from 0 to 100 points, with higher scores indicating worse health-related quality of life.

At Week 24
Change from baseline in Skindex-29+3 Emotion domain scores
Lasso di tempo: At Week 24

The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE.

At Week 24
Change from baseline in Skindex-29+3 Function domain scores
Lasso di tempo: At Week 24

The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE.

At Week 24
Change from baseline in Skindex-29+3 Lupus-Specific domain scores
Lasso di tempo: At Week 24

The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE.

At Week 24
Change from baseline in Skindex-29+3 Total score
Lasso di tempo: At Week 24

The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE.

At Week 24
Time from IP start date to CLASI-70 response.
Lasso di tempo: From Week 0/Day 1 up to Week 24

To assess the efficacy of anifrolumab compared with placebo on the onset of reduction in skin manifestations in participants with chronic and/or subacute CLE.

From Week 0/Day 1 up to Week 24
Time from IP start date to CLASI-50 response.
Lasso di tempo: From Week 0/Day 1 up to Week 24

To assess the efficacy of anifrolumab compared with placebo on the onset of reduction in skin manifestations in participants with chronic and/or subacute CLE.

From Week 0/Day 1 up to Week 24

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Number of participants with adverse events
Lasso di tempo: Screening (up to and including 42 days before Day 1) until Safety Follow-up Period (12 weeks from Week 52/EDV)

To evaluate the safety and tolerability of anifrolumab compared with placebo in participants with CLE.

Screening (up to and including 42 days before Day 1) until Safety Follow-up Period (12 weeks from Week 52/EDV)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

29 giugno 2024

Completamento primario (Effettivo)

2 novembre 2026

Completamento dello studio (Stimato)

10 agosto 2027

Date di iscrizione allo studio

Primo inviato

1 agosto 2023

Primo inviato che soddisfa i criteri di controllo qualità

22 agosto 2023

Primo Inserito (Effettivo)

29 agosto 2023

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

12 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

10 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • D346BC00001
  • 2021-003698-70 (Numero EudraCT)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Periodo di condivisione IPD

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Criteri di accesso alla condivisione IPD

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .